The Cholestasis drugs in development market research report provides comprehensive information on the therapeutics under development for Cholestasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cholestasis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cholestasis and features dormant and discontinued products.
GlobalData tracks 16 drugs in development for Cholestasis by 15 companies/universities/institutes. The top development phase for Cholestasis is preclinical with ten drugs in that stage. The Cholestasis pipeline has 14 drugs in development by companies and two by universities/ institutes. Some of the companies in the Cholestasis pipeline products market are: Ipsen, Vivet Therapeutics and Takeda Pharmaceutical.
The key targets in the Cholestasis pipeline products market include Bile Acid Receptor (Farnesoid X Activated Receptor or Farnesol Receptor HRR 1 or Nuclear Receptor Subfamily 1 Group H Member 4 or Retinoid X Receptor Interacting Protein 14 or FXR or NR1H4), Bile Salt Export Pump (ATP Binding Cassette Sub Family B Member 11 or ABCB11), and Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2).
The key mechanisms of action in the Cholestasis pipeline product include Bile Acid Receptor (Farnesoid X Activated Receptor or Farnesol Receptor HRR 1 or Nuclear Receptor Subfamily 1 Group H Member 4 or Retinoid X Receptor Interacting Protein 14 or FXR or NR1H4) Agonist with three drugs in Phase II. The Cholestasis pipeline products include two routes of administration with the top ROA being Oral and two key molecule types in the Cholestasis pipeline products market including Small Molecule, and Gene Therapy.
Cholestasis overview
Cholestasis is the slowing or stalling of bile flow from liver. Liver produces bile and delivers it to digestive system through a network of vessels called bile ducts. Bile ducts run through liver (intrahepatic ducts) as well as outside of it (extrahepatic ducts). They connect liver, gallbladder, pancreas and small intestine. Bile that can’t reach your intestines can also cause problems in your digestive system.
For a complete picture of Cholestasis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
